All In Biotech

Drug Trial Radar · NCT00506441

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-center, Withdrawal Study Comparing MCI-196 v.s Placebo Following A 12-Week Dose Titration Period With MCI-196 in Stage V Subjects on Dialysis With Hyperphosphatemia

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 245 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

245

Actual

Start

Sep 2007

Primary completion

Sep 2009

Study completion Sep 2009

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
First posted
Jul 25, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, flexible dose titration, the third period is a placebo-controlled withdrawal comparing MCI-196 with placebo for 4 weeks.

Conditions

  • Chronic Kidney Disease
  • Dialysis
  • Hyperphosphatemia

Interventions

  • MCI-196Drug

    3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose (Open-label) and 4 weeks of double blind

  • PlaceboDrug

    3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Change in Serum Phosphorus From Week 12 to Week 16Time frame: 4 weeks (Week 12 to Week 16)

Locations

39 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Glendale, Arizona

  • Site not named

    Tempe, Arizona

  • Site not named

    Hot Springs, Arkansas

  • Site not named

    Paragould, Arkansas

  • Site not named

    Pine Bluff, Arkansas

  • Site not named

    Fountain Valley, California

  • Site not named

    La Mesa, California

  • Site not named

    Long Beach, California

  • Site not named

    Lynwood, California

  • Site not named

    Orange, California

  • Site not named

    San Diego, California

  • Site not named

    Whittier, California

  • Site not named

    Brandon, Florida

  • Site not named

    Hudson, Florida

  • Site not named

    Lauderdale Lakes, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Augusta, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Macon, Georgia

  • Site not named

    Evanston, Illinois

  • Site not named

    Evergreen Park, Illinois

  • Site not named

    Fort Wayne, Indiana

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Springfield, Massachusetts

  • Site not named

    Eatontown, New Jersey

  • Site not named

    Flushing, New York

  • Site not named

    Springfield Gardens, New York

  • Site not named

    Allentown, Pennsylvania

  • Site not named

    Lewistown, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Columbia, South Carolina

  • Site not named

    Orangeburg, South Carolina

  • Site not named

    Sumter, South Carolina

  • Site not named

    San Antonio, Texas

  • Site not named

    Alexandria, Virginia

  • Site not named

    Portsmouth, Virginia

  • Site not named

    Richmond, Virginia

  • Site not named

    West Allis, Wisconsin

  • Site not named

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.